Elranatamab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A bispecific monoclonal antibody against human CD3, a T-cell surface antigen, and human B-cell maturation antigen (BCMA; TNFRSF17), a tumor-associated antigen (TAA) expressed on plasma cells, with potential antineoplastic activity. Upon administration, elranatamab binds to both CD3 on T-cells and BCMA expressed on malignant plasma cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against BCMA-expressing plasma cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.

**Synonyms:** - Anti-CD3/Anti-BCMA Bispecific Antibody PF-06863135 - B-cell Maturation Antigen-CD3 Bispecific Antibody PF-06863135 - BCMA x CD3 Bispecific Antibody PF-06863135 - BCMA-CD3 Bispecific Ab PF-06863135 - ELRANATAMAB - Elranatamab-bcmm - Elrexfio - PF 06863135 - PF-06863135 - PF06863135 - RN 613 - RN-613 - RN613